This involves monitoring prostate cancer in its localized stage until your doctor feels that further treatment is needed to halt the disease at a curable stage. According to the American Society of ...

Diffusion basis spectrum imaging combined with AI enhances diagnostic accuracy for prostate cancer A study published in the ...

Jason Junkins, M.D., and his wife, Angela For local urgent care physician Jason Junkins, M.D., prostate cancer was not on his ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announces that its next-generation PSMA1 PET2 imaging ...

The prostate cancer patients were on average 63 (±6.3) years old at diagnosis. For 242 (65%) patients, the PSA value at diagnosis was below 10 ng/ml; the clinical stage was classified as T1-T2a ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

Telix Pharmaceuticals’ Illuccix gets US FDA label expansion to add patient selection for radioligand therapy: Melbourne, Australia Wednesday, June 25, 2025, 17:00 Hrs [IST] Melb ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally.

According to the EAU-ESTRO-SIOG 2018 guidelines, the biochemical disease-free survival for Gleason 6 prostate cancer at 5 years ranges from 71-93% and at 10 years from 65-85%.

Prostate cancer can be difficult to detect in its beginning stages — here's what to look out for to help catch it before it ...

Dr. Michael Rezaee, a urologist at Concord Hospital-Laconia, is a guardian of prostate health in a state whose aging ...

Background: In this population-based study, we investigated the degree of concordance between Gleason scores obtained from prostate biopsies and those obtained from prostatectomy specimens, as ...